BOSTON SCIENTIFIC LAUNCHES NEXT-GENERATION DES
Boston Scientific announced the launch of its Taxus Liberte paclitaxel-eluting coronary stent system in 18 countries.
The Liberte drug-eluting stent (DES) features the Veriflex stent design, a highly flexible cell geometry with thin struts and uniform cell distribution. This platform offers improved deliverability and conformability in challenging anatomy. It also features the enhanced TrakTip catheter tip, mounted on the Maverick2 delivery catheter, which provides better lesion crossability. In addition, TrakTip has a low lesion-entry profile, which further improves crossability.
Boston Scientific received the CE Mark for the bare metal Liberte stent in December 2003 and plans to launch the Liberte DES in Europe later this year. In the U.S., Boston Scientific announced enrollment in the ATLAS clinical trial, a pivotal study designed to support FDA approval of the Taxus Liberte stent system.